Carbapenem | Jotup

Shionogi to Present New Data on FETROJA® (cefiderocol) at IDWeek 2020

Retrieved on:

Monday, October 19, 2020

Biotechnology, General Health, Pharmaceutical, Health, Chemical compounds, Organic compounds, Cefiderocol, Siderophores, Carbapenem, Shionogi, Carbapenem antibiotics, Pyrrolidines, Ertapenem, Antibiotic, Beta-lactam, FETROJA® (cefiderocol) for injection, Shionogi

Shionogi & Co., Ltd. (hereafter Shionogi) today announces that 18 abstracts on FETROJA (cefiderocol), including two oral presentations, will be shared at IDWeek.

Key Points:

Shionogi & Co., Ltd. (hereafter Shionogi) today announces that 18 abstracts on FETROJA (cefiderocol), including two oral presentations, will be shared at IDWeek.
FETROJA has also demonstrated in vitro activity against certain bacteria that contain very problematic resistant enzymes such as ESBLs, AmpC, serine- and metallo-carbapenemases.
FETROJA is contraindicated in patients with a known history of severe hypersensitivity to cefiderocol or other beta-lactam antibacterial drugs, or any other component of FETROJA.
Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd. based in N.J. For more information on Shionogi Inc., please visit www.shionogi.com .

OpGen Announces Award of German Government Grant Funding to its Subsidiary Curetis and Collaborators

Retrieved on:

Wednesday, September 30, 2020

Medical specialties, Branches of biology, Clinical medicine, Pathogenic bacteria, Healthcare-associated infections, Carbapenem, Moraxellaceae, Pseudomonadales, Drug resistance, Efflux, Acinetobacter, Porin

Furthermore, the project aims to address resistance mechanisms in difficult-to-treat Gram-negative pathogens such as Enterobacteria, Pseudomonas and Acinetobacter.

Key Points:

Furthermore, the project aims to address resistance mechanisms in difficult-to-treat Gram-negative pathogens such as Enterobacteria, Pseudomonas and Acinetobacter.
Curetis role during the collaborative research project is to provide research on innovative detection methods for carbapenem resistance based on porin loss and efflux pump overexpression.
Resistance is often conferred by mechanisms such as porin loss or efflux pump overexpression, not adequately covered by current diagnostics.
This press release includes statements regarding the receipt of a grant from the German government by Curetis GmbH.

Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections

Retrieved on:

Thursday, September 24, 2020

Medical specialties, Clinical medicine, Medicine, RTT, Carbapenem, Bacterial diseases, Pyelonephritis, Tebipenem, Urinary tract infection, Nontuberculous mycobacteria, Infection

If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval inthe United States.

Key Points:

If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval inthe United States.
Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by theFDAfor the treatment of cUTI and AP.
In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in complicated urinary tract infection and acute pyelonephritis.
Spero is also advancing SPR720, its novel oral therapy product candidate designed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Shionogi Launches FETCROJA® (cefiderocol) in the United Kingdom for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options

Retrieved on:

Tuesday, September 15, 2020

Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Health, Medical specialties, Infectious diseases, Healthcare-associated infections, Shionogi, Carbapenem, Hospital-acquired infection, Cefiderocol, Hospital-acquired pneumonia

Cefiderocol can now be used to treat some of the most life-threatening infections in patients for whom there are limited or no alternative treatment options.

Key Points:

Cefiderocol can now be used to treat some of the most life-threatening infections in patients for whom there are limited or no alternative treatment options.
Similar to nosocomial pneumonia patients with carbapenem-resistant Gram-negative infections, cefiderocol may be considered as a treatment option.
Shionogi has a strong heritage in the field of anti-infectives and has been developing antimicrobial therapies for more than 60 years.
Shionogi B.V. is the European headquarters of Shionogi & Co., Ltd. For more information on Shionogi B.V., please visit www.shionogi.eu .

Venatorx Pharmaceuticals Awarded up to $44.2 Million to Advance Novel Inhibitors of Penicillin Binding Proteins targeting WHO Critical Priority Pathogen

Retrieved on:

Monday, July 27, 2020

75N93020C00016, the total estimated cost of the base period for this contract is approximately $3.2 million.

Key Points:

75N93020C00016, the total estimated cost of the base period for this contract is approximately $3.2 million.
Venatorx has the potential to receive funding of up to $44.2 million, if all project milestones are met.
A. baumannii is ranked as a Priority 1: Critical carbapenem resistant pathogen on the World Health Organizations list of bacteria for which new antibiotics are urgently needed.
Venatorx is a private pharmaceutical company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections.

ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development

Retrieved on:

Monday, July 20, 2020

Medical specialties, Health, Infectious diseases, Hospital-acquired infection, Pseudomonas aeruginosa, Bacteremia, Pneumonia, Ventilator-associated pneumonia, Infection, Urinary tract infection, Carbapenem, Neonatal infection

This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.

Key Points:

This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met.
Any funding beyond the initial $4.9 million is at the sole discretion of CARB-X and subject to available funds.
At ContraFect, we remain committed to developing superior therapeutic agents with the potential to improve clinical outcomes and save lives.
Invasive P. aeruginosa infections, including ventilator-associated pneumonia, blood stream infections, complicated urinary tract infections, and infections following surgery carry some of the highest rates of mortality among hospital acquired infections.

FDA Approves Merck’s RECARBRIO™ (imipenem, cilastatin, and relebactam) for the Treatment of Adults with Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)

Retrieved on:

Friday, June 5, 2020

RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity to any component of RECARBRIO.

Key Points:

RECARBRIO is contraindicated in patients with a history of known severe hypersensitivity to any component of RECARBRIO.
RECARBRIO is a combination of imipenem, a carbapenem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor.
RECARBRIO met the primary and key secondary endpoints, demonstrating non-inferiority to PIP/TAZ in 28-day all-cause mortality and clinical response at early follow-up, respectively.
Todays approval is further affirmation of Mercks steadfast commitment to meeting the needs of the health care community.

FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Retrieved on:

Thursday, June 4, 2020

Drugs, RTT, Antibiotics, Enantiopure drugs, Carbapenem antibiotics, Fluoroquinolone antibiotics, Imipenem/cilastatin/relebactam, Imipenem/cilastatin, Levofloxacin, Relebactam, Imipenem, Carbapenem

SILVER SPRING, Md., June 4, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.

Key Points:

SILVER SPRING, Md., June 4, 2020 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older.
Recarbrio was previously FDA-approved to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options.
"These efforts provide more options to fight serious bacterial infections and get new, safe and effective therapies to patients as soon as possible."
This designation is given to antibacterial and antifungal drug products intended to treat serious or life-threatening infections under the Generating Antibiotic Incentives Now (GAIN) title of the FDA Safety and Innovation Act.

FDA Accepts Shionogi’s Supplemental New Drug Application with Priority Review for FETROJA® (cefiderocol) for the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia

Retrieved on:

Monday, June 1, 2020

Shionogi submitted the sNDA for FETROJA for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Gram-negative pathogens.

Key Points:

Shionogi submitted the sNDA for FETROJA for the treatment of adult patients with hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible Gram-negative pathogens.
Safety was investigated up to 28 days after the end of treatment unless there was an ongoing serious adverse event(s).
The safety and efficacy of FETROJA have not been established for the treatment of nosocomial pneumonia, bloodstream infections or sepsis.
Reserve FETROJA for use in patients who have limited or no alternative treatment options for the treatment of cUTI.

Zai Lab Announces First Chinese Patient Dosed in the Global Phase 3 ATTACK Trial of Sulbactam-Durlobactam for Patients with Carbapenem-Resistant Acinetobacter Infections

Retrieved on:

Monday, May 18, 2020

Infectious diseases, Moraxellaceae, Bacteria, Microbiology, Healthcare-associated infections, Gram-negative bacteria, Acinetobacter baumannii, Pathogenic bacteria, Acinetobacter, Carbapenem

With over 200,000 occurrences estimated each year, China ranks among the countries with the highest incidence of A. baumannii infections in the world.

Key Points:

With over 200,000 occurrences estimated each year, China ranks among the countries with the highest incidence of A. baumannii infections in the world.
ATTACK is a global, two-part Phase 3 registrational trial enrolling approximately 300 patients with pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii.
A Phase 2 trial and several Phase 1 trials of SUL-DUR have recently been completed with positive results for pharmacokinetics and safety/tolerability.
These forward-looking statements should not be relied upon as representing Zai Labs views as of any date subsequent to the date of this press release.